Clinical Trials
61 trialsIACE-OS
Shanghai 6th People's Hospital
ECWHCCFLACC
First Affiliated Hospital of Guangxi Medical University
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Fudan University
FUMS-EDJS2024
Fudan University
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
Nanjing First Hospital, Nanjing Medical University
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
The First People's Hospital of Lianyungang
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma
Fudan University
Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer
Sun Yat-sen University
FTANLCNDG
Qianfoshan Hospital
Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer
Anhui Chest Hospital
Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial
The First Affiliated Hospital with Nanjing Medical University
Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
The Affiliated Hospital of Xuzhou Medical University
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
First Affiliated Hospital of Guangxi Medical University
Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
Endostar for Locally Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
RELIEF
Shanghai Chest Hospital
SLICER
Peking University
A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
China Three Gorges University, Yichang, China
SBRTLCES
Peking University Third Hospital
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
Peking University Cancer Hospital & Institute
Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma
Tianjin Medical University Cancer Institute and Hospital
CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer
Zhejiang Cancer Hospital
Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC
Third Military Medical University
TENDENCY
Hebei Medical University Fourth Hospital
Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma
Jiangsu Cancer Institute & Hospital
Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer
Zhejiang Cancer Hospital
A Trial of Endostar in Patients With Carcinoma of the Head and Neck
China International Medical Foundation
Rh-Endostatin (Endostar®) Continuous Intravenous Infusion
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
First Affiliated Hospital of Guangxi Medical University
Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer
Affiliated Hospital of North Sichuan Medical College
A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC
Sun Yat-sen University
Endostar First-line Treatment of Advanced NSCLC
China Medical University, China
Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma
Peking University Cancer Hospital & Institute
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
Xinqiao Hospital of Chongqing
Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
First Affiliated Hospital of Guangxi Medical University
Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients
Eastern Hepatobiliary Surgery Hospital
Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Fudan University
Trial of Endostar Combined With CHOPT for T Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
Tianjin Medical University Cancer Institute and Hospital
Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer
Peking University
Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
Hunan Province Tumor Hospital
Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
Zhejiang University
Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.
Peking University Third Hospital
Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC
Zhejiang University
Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer
Xinjiang Medical University
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB
Xinjiang Medical University